Codexis, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

27 Feb 2025

CDXS

10-K: Codexis, Inc. Reports Fiscal Year 2024 Results, Focuses on Pharma Biocatalysis and RNAi Manufacturing

Codexis, Inc. announces its 2024 financial results, highlighting its strategic focus on pharma biocatalysis and the ECO Synthesis manufacturing platform for RNAi therapeutics.

NASDAQ

28 Feb 2024

CDXS

Codexis, INC

10-K: Codexis Outlines Share Structure and Strategic Shift in Annual 10-K Filing

Codexis's annual 10-K filing details its share structure, strategic shift towards pharmaceutical manufacturing and RNAi therapeutics, and discontinuation of certain biotherapeutic programs.